Parameter
| Biomarker | t(8;21)/inv(16)/t(16;16) fusion transcript | Full name | t(8;21) (RUNX1-RUNX1T1)/inversion 16 (CBFβ-MYH11)/t(16;16) (CBFβ-MYH11) fusion transcript | Molecular Type | Nucleic acid (RNA) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis, monitoring, prognosis | ||
| Disease | Acute Myeloid Leukemia (AML) | Disease Subtypes | / | ||
| Organ | Blood, bone marrow | Test Sample / Technology Platform | Bone marrow (quantitative polymerase chain reaction, QPCR) | ||
| Pathobiological Mechanisms | Chromosomal translocation generates fusion proteins, driving leukemia development and sensitivity to chemotherapy | ||||
| Clinical Availability Status | Clinically available/guideline-recommended: Included in the CBF-AML diagnostic criteria for efficacy monitoring. | ||||
| Notes and Dynamics | The first-line treatment regimen combining rituximab and oxorubicin improves prognosis, and continuous monitoring of fusion transcripts guides treatment adjustments. | ||||